42 results about "Clinical course" patented technology

The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.

The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).

Genes, SNP markers and haplotypes of susceptibility or predisposition to hypertension (HT) are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for HT using polymorphisms in the HT risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of HT. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of HT.

Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.

The present invention relates to methods and kits for diagnosing, ascertaining the clinical course a of myelodysplastic syndrome(MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides method and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.

A system, non-transitory computer readable medium, and method are provided for determining patient care services for a patient being treated for a life-threatening or life-limiting progressive illness. Patient symptoms are identified by receiving data comprising personal health information of a patient. The level of distress of the patient is determined by analyzing the data comprising personal health information of the patent. A score is established based on criteria comprising the level of distress of the patient and a severity of the patient symptoms. The score correlates the level of distress of the patient with a clinical course of the life-threatening or life-limiting progressive illness. One or more patient care services appropriate for the clinical course of the life-threatening or life-limiting progressive illness and the level of distress of the patient is determined based on the score.

The present invention provides an application of aortic root angioplasty in Stanford type A aortic dissection clinical procedures. During the clinical treatment of Stanford type A aortic dissection, the premise of not using new surgical materials and increasing the cost of surgery It can basically eliminate the proximal dissection cavity of the aortic root, avoid anastomotic bleeding, avoid the compression of the coronary arteries by the proximal dissection cavity of the aortic root, and effectively avoid long-term false lumen caused by the proximal aortic root. There is formation of pseudoaneurysm caused by proximal neoplasia of the aortic root or anastomotic stoma. Reduce the possibility of bleeding while avoiding complications caused by massive blood transfusion, shorten the operation time, improve the success rate of the operation, reduce the difficulty of Stanford type A aortic dissection, and facilitate the promotion of Stanford type A aortic dissection and popularity.